The risk of primary and contralateral breast cancer after ovarian cancer inBRCA1/BRCA2mutation carriers

Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients

(2011) P. M. L. H. Vencken et al.   ANNALS OF ONCOLOGY

Preventive therapy for breast cancer: a consensus statement

(2011) Jack Cuzick et al.   LANCET ONCOLOGY

Therapeutic Approaches for Women Predisposed to Breast Cancer

(2010) Katherine L. Nathanson et al.   Annual Review of Medicine

Bilateral prophylactic mastectomy in women with inherited risk of breast cancer – Prevalence of pain and discomfort, impact on sexuality, quality of life and feelings of regret two years after surgery

(2010) Jessica Gahm et al.   BREAST

Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer

(2010) Kerryn W. Reding et al.   BREAST CANCER RESEARCH AND TREATMENT

Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age

(2010) Dorina M. van der Kolk et al.   BREAST CANCER RESEARCH AND TREATMENT

Common Breast Cancer Susceptibility Alleles and the Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Implications for Risk Prediction

(2010) A. C. Antoniou et al.   CANCER RESEARCH

Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and Mortality

(2010) Susan M. Domchek   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer

(2010) Daniel P. Silver et al.   JOURNAL OF CLINICAL ONCOLOGY

BRCA1-Associated Breast Cancers Present Differently From BRCA2-Associated and Familial Cases: Long-Term Follow-Up of the Dutch MRISC Screening Study

(2010) Adriana J. Rijnsburger et al.   JOURNAL OF CLINICAL ONCOLOGY

BRCA mutations in the management of breast cancer: the state of the art

(2010) Steven A. Narod   Nature Reviews Clinical Oncology

Uptake, Time Course, and Predictors of Risk-Reducing Surgeries in BRCA Carriers

(2009) Mary S. Beattie et al.   Genetic Testing and Molecular Biomarkers

BRCA1 and implications for response to chemotherapy in ovarian cancer

(2009) Jennifer E. Quinn et al.   GYNECOLOGIC ONCOLOGY

Contralateral Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers

(2009) Monika K. Graeser et al.   JOURNAL OF CLINICAL ONCOLOGY

Survival Analysis of Cancer Risk Reduction Strategies forBRCA1/2Mutation Carriers

(2009) Allison W. Kurian et al.   JOURNAL OF CLINICAL ONCOLOGY

Meta-analysis of Risk Reduction Estimates Associated With Risk-Reducing Salpingo-oophorectomy in BRCA1 or BRCA2 Mutation Carriers

(2009) T. R. Rebbeck et al.   JNCI-Journal of the National Cancer Institute

Predictors of Contralateral Prophylactic Mastectomy in Women With a BRCA1 or BRCA2 Mutation: The Hereditary Breast Cancer Clinical Study Group

(2008) Kelly A. Metcalfe et al.   JOURNAL OF CLINICAL ONCOLOGY

Risk-Reducing Salpingo-Oophorectomy for the Prevention of BRCA1- and BRCA2-Associated Breast and Gynecologic Cancer: A Multicenter, Prospective Study

(2008) Noah D. Kauff et al.   JOURNAL OF CLINICAL ONCOLOGY

“BRCAness” Syndrome in Ovarian Cancer: A Case-Control Study Describing the Clinical Features and Outcome of Patients With Epithelial Ovarian Cancer Associated WithBRCA1andBRCA2Mutations

(2008) David S.P. Tan et al.   JOURNAL OF CLINICAL ONCOLOGY